FDA Warns of Risks in Compounded GLP-1 Drugs
Adults using compounded semaglutide or tirzepatide face products that the FDA has not reviewed for safety or quality.
Updated on Nov. 6, 2026 in Weight Loss
Live Poll
Would you trust a telehealth company to sell you weight loss medication?
The FDA warned patients and doctors about the risks of unapproved compounded GLP-1 weight loss drugs, including compounded versions of semaglutide and tirzepatide, which are not reviewed for safety, effectiveness, or quality before sale. The agency also issued warnings to telehealth companies, ingredient suppliers, and outsourcing facilities over retatrutide and cagrilintide compounding, which is not legally permitted.
Why it matters
Patients using compounded versions of popular weight loss medications may have no assurance of what they are actually receiving, since some products carry labels from pharmacies that do not exist or falsely use the name of a real pharmacy. The warning arrives as adverse event reports continue to accumulate and as counterfeit versions of brand-name products circulate.
The figures come from FDA adverse event reports, a passive surveillance system in which clinicians and others voluntarily report problems, so they cannot establish how often harm occurs. The 990 semaglutide and more than 730 tirzepatide reports as of May 31, 2026 are likely an undercount, and the total number of affected patients remains unknown.
The players
U.S. Food and Drug Administration (FDA)
The federal agency that approves prescription drugs and oversees drug safety, including reviewing brand-name GLP-1 medications and monitoring adverse event reports for compounded versions.
The details
Compounded drugs are made by pharmacies or outsourcing facilities to match a prescription, and they fall outside the FDA's approval process that reviews brand-name drugs for safety, effectiveness, and manufacturing quality. Some compounders are selling salt forms of semaglutide that are not found in approved drugs, and some telehealth companies ship medication without a doctor screening the patient beforehand. Shipping problems add another layer of risk, as some compounded GLP-1 shipments have arrived warm or without proper ice packs, which can affect a medication's stability.
Timeline
As of May 31, 2026, the FDA had received 990 adverse event reports tied to compounded semaglutide.
On November 6, 2026, the FDA published its warning on unapproved compounded GLP-1 drugs.
Health Landscape
Compounded GLP-1 products grew during the period when brand-name semaglutide and tirzepatide were in shortage, and the FDA's current warning addresses the market that persisted afterward. The agency's action reflects a broader gap between the approved drug pipeline, which requires safety and quality review, and compounded alternatives that do not.
If you or someone you know uses a compounded semaglutide or tirzepatide product, it is worth asking your prescriber where the medication was made and whether it has been verified, and being alert to unusual side effects. Anyone considering a telehealth weight loss prescription should confirm that a licensed clinician reviewed their history before shipment, and it is worth discussing any concerns about your current medication with your doctor.
The takeaway
The most important point is that compounded GLP-1 products are not reviewed by the FDA before sale, so their identity, labeling, and quality can be harder to verify than brand-name drugs. Checking that a medication's pharmacy is real and that a licensed clinician prescribed it is a practical step worth taking.
Further reading
For more on the medications at the center of this warning, see our Weight Loss coverage.
More information
Report a suspected problem through the FDA MedWatch adverse event reporting system.
Source note: This article includes information reported by Atlantanewsfirst.
Live Poll
Would you trust a telehealth company to sell you weight loss medication?
